Prediabetes Market
Prediabetes Market Size, Share & Trends Analysis Report by Drug Class (Biguanide (Metformin), Thiazolidinediones (TZDs), Glucagon-like Peptide-1 Agonists (GLP-1), SGLT2 Inhibitors, DPP-4 Inhibitors, and Others), by Route of Administration (Oral, and Injectable), and by Age Group (Children (12 to 18 Years), Adult (18 to 50 Years), and Elderly (Above 50 Years)) Forecast Period (2025-2035)
Industry Overview
Prediabetes market was valued at $0.35 billion in 2024 and is projected to reach $1.1 billion by 2035, growing at a CAGR of 11.3 % during the forecast period (2025–2035). The market growth is fueled by the increasing incidence of prediabetes, growing awareness of early diagnosis and treatment, and the evolution of digital health solutions. The rising usage of continuous glucose monitoring (CGM) devices, wearables, and AI-based predictive analytics is substantially improving patient outcomes and disease prevention. Government public health programs, increasing insurance coverage for preventive services, investments in personalized medicine, and behavioral interventions are among the prime drivers of market growth. Another trend is the inclusion of telemedicine, mobile health apps, and digital therapeutics into pre-diabetes disease management models, which is revolutionizing disease management, patient engagement, and early intervention approaches.
Market Dynamics
Innovations in Personalized Monitoring and Digital Health Solutions
Technological advances in personalised monitoring and digital health platforms are revolutionising the prediabetes market by enabling early diagnosis, ongoing monitoring, and early intervention among high-risk populations. Highly advanced wearable technology and biosensors provide real-time monitoring of glucose levels, physical activity, and other metabolic markers, allowing for timely therapies. Artificial intelligence algorithms interpret patient data to detect trends and forecast disease progression, adding personalization to treatment regimens. Mobile health apps (mHealth) offer patients personal lifestyle advice, medication reminders, and dietary tracking, promoting enhanced self-management. Remote patient monitoring (RPM) programs connect patients with their healthcare professionals, initiating prompt medical advice and intervention. Telemedicine systems interface with digital health tools, providing virtual visits and ongoing contact for high-risk populations. Cloud-based electronic health records (EHRs) support easy integration of data, enhancing care coordination and patient outcomes. Genomic and precision medicine technology help with risk classification, allowing for personalised treatment regimens. Smart insulin delivery devices and computerised coaching programs improve treatment plan adherence.
Increasing Awareness Campaigns for Prediabetes Prevention and Early Detection
Government and institutions are introducing awareness initiatives to enhance public knowledge and early detection, thus driving demand for preventive diagnostics and care. For instance, in November 2023, the US Centers for Disease Control and Prevention (CDC) partnered with the Ad Council and other groups to launch new public service announcements (PSAs) in the form of a prediabetes awareness campaign as part of the Do I Have Prediabetes? Initiative. The initiative aims to raise awareness about prediabetes, a disorder that affects approximately one-third of American adults, or over 98 million individuals, although 81% are unaware of it. The campaign urges adults between the ages of 40–65 to complete a one-minute online risk test and, if at increased risk, to visit a healthcare provider and be a part of the CDC's National Diabetes Prevention Program.
Rising Focus on Prevention Through Advanced Therapeutics and Long-Term Interventions
The market expansion is led mainly by the increased focus on prevention in the treatment of prediabetes, especially tirzepatide's potential to substantially lower diabetes progression risk. For instance, in August 2024, Eli Lilly and Company reported positive topline three-year SURMOUNT-1 study (176-week treatment duration) results, assessing the efficacy and safety of once-weekly tirzepatide (Mounjaro and Zepbound) for long-term weight management and slowing the progression to diabetes in obese or overweight adults with pre-diabetes. Obese or overweight adults with pre-diabetes had a 94% ii reduced risk of developing type 2 diabetes after receiving weekly. Furthermore, treatment with tirzepatide led to weight loss over the duration of the treatment, with adults receiving 15 mg having a 22.9% average weight decrease over the body compared to 2.1% in the case of placebo in adults with pre-diabetes, obesity, or an overweight condition at the end of the treatment duration.
Market Segmentation
- Based on the drug class, the market is segmented into biguanide (metformin), thiazolidinediones (TZDs), glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, and others.
- Based on the route of administration, the market is segmented into oral and injectable.
- Based on the age group, the market is segmented into children (12 to 18 Years), adults (18 to 50 Years), and the elderly (above 50 Years).
Biguanide (Metformin): A Key Segment in Market Growth
Biguanides, especially metformin, are oral drugs that control blood sugar levels in Type 2 and gestational diabetes by reducing liver glucose release and boosting muscle sensitivity to insulin, hence improving glucose absorption; moreover, they delay the conversion of carbs to sugar. Metformin, available in extended- and immediate-release tablets and capsules, is marketed under different names such as Glucophage and Glumetza. Although the most common adverse effects include gastrointestinal issues such as diarrhoea, nausea, and bloating, as well as a metallic taste, chronic treatment can contribute to a vitamin B12 deficiency. While uncommon, lactic acidosis is one of the severe adverse effects that can occur, although at a higher risk in patients with reduced renal function; hypoglycemia is only probable when used in combination with other glucose-lowering medications.
Regional Outlook
The global prediabetes market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Maintains Strong Market Position
North America holds a significant share, owing to the market growth is led mainly by the initiative and regulatory support of the US government are fuelling market expansion in diabetes management. For instance, in December 2024, the US FDA approved the initial generic formulation of Victoza (liraglutide injection) 18 milligram/3 milliliter, a GLP-1 receptor agonist administered to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, in addition to diet and exercise. Additionally, Byetta (exenatide) was approved by the FDA as the first generic in this class. During the present shortage of liraglutide injectable and other related GLP-1 medications, the FDA is speeding up the review of generic drug applications to increase patient access.
Market Players Outlook
The major companies operating in the global Prediabetes market include Abbott Laboratories, AstraZeneca, Eli Lilly and Co., Medtronic MiniMed, Inc., Nordisk A/S, among others., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In August 2024, Abbott partnered with Medtronic to co-develop an integrated continuous glucose monitoring (CGM) system based on Abbott's most sophisticated, world-class FreeStyle Libre technology, coupled with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. AID systems enhance health outcomes and alleviate the burden of ongoing decision-making for individuals with diabetes using intensive insulin as part of their regimen. AID systems can be useful for both Type 1 and Type 2 diabetics; over 11 million individuals globally require numerous daily injections of rapid-acting insulin.
- In June 2024, Aphaia Pharma announced that its Phase 2 trial of the company's leading oral glucose formulation for the treatment of prediabetes met its primary endpoint. The trial indicated a statistically significant increase in glucose tolerance in individuals with a pathological Oral Glucose Tolerance Test (OGTT) after 6 weeks of APHD-012 treatment compared to placebo, with an encouraging safety profile.
The Report Covers
- Market value data analysis of 2024 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global prediabetes market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Prediabetes Market Sales Analysis – Drug Class | Route of Administration | Age Group ($ Million)
- Prediabetes Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Prediabetes Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Global Prediabetes Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Prediabetes Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Prediabetes Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Prediabetes Market Revenue and Share by Manufacturers
- Prediabetes Drug Class Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Abbott Laboratories
- Overview
- Drug Class Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- AstraZeneca
- Overview
- Drug Class Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Eli Lilly and Co.
- Overview
- Drug Class Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Medtronic MiniMed, Inc.
- Overview
- Drug Class Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Nordisk A/S
- Overview
- Drug Class Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Abbott Laboratories
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Drug Class Launch
- Partnership And Collaboration
- Global Prediabetes Market Sales Analysis by Drug Class ($ Million)
- Biguanide (Metformin)
- Thiazolidinediones (TZDs)
- Glucagon-like Peptide-1 Agonists (GLP-1)
- SGLT2 Inhibitors
- DPP-4 Inhibitors
- Others
- Global Prediabetes Market Sales Analysis by Route of Administration ($ Million)
- Oral
- Injectable
- Global Prediabetes Market Sales Analysis by Age Group ($ Million)
- Children (12 to 18 Years)
- Adult (18 to 50 Years)
- Elderly (Above 50 Years)
- Regional Analysis
- North American Prediabetes Market Sales Analysis – Drug Class | Route of Administration | Age Group ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Prediabetes Market Sales Analysis – Drug Class | Route of Administration | Age Group ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Prediabetes Market Sales Analysis – Drug Class | Route of Administration | Age Group ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And others)
- Rest of Asia-Pacific
- Rest of the World Prediabetes Market Sales Analysis – Drug Class | Route of Administration | Age Group ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aphaia Pharma AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Apollo Hospitals Enterprise Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boston Heart Diagnostics Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Caelus Health
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- DDM Health Ltd
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Diabetomics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Medtronic MiniMed, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck KGaA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Nordisk A/S
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- PharmaLinea
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Trivitron Healthcare
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Valbiotis SA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- WebMD LLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Prediabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)
2. Global Biguanide (Metformin) Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
3. Global Thiazolidinediones (TZDs) Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
4. Global Glucagon-Like Peptide-1 Agonists (GLP-1) Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
5. Global SGLT2 Inhibitors Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
6. Global DPP-4 Inhibitors Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
7. Global Other Drug Class Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
8. Global Prediabetes Market Research And Analysis By Route Of Administration, 2024-2035 ($ Million)
9. Global Oral Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
10. Global Injectable Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
11. Global Prediabetes Market Research And Analysis By Age Group, 2024-2035 ($ Million)
12. Global Prediabetes Children Market Research And Analysis By Region, 2024-2035 ($ Million)
13. Global Prediabetes Adult Market Research And Analysis By Region, 2024-2035 ($ Million)
14. Global Prediabetes Elderly Market Research And Analysis By Region, 2024-2035 ($ Million)
15. Global Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
16. North American Prediabetes Market Research And Analysis By Country, 2024-2035 ($ Million)
17. North American Prediabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)
18. North American Prediabetes Market Research And Analysis By Route Of Administration, 2024-2035 ($ Million)
19. North American Prediabetes Market Research And Analysis By Age Group, 2024-2035 ($ Million)
20. European Prediabetes Market Research And Analysis By Country, 2024-2035 ($ Million)
21. European Prediabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)
22. European Prediabetes Market Research And Analysis By Route Of Administration, 2024-2035 ($ Million)
23. European Prediabetes Market Research And Analysis By Age Group, 2024-2035 ($ Million)
24. Asia-Pacific Prediabetes Market Research And Analysis By Country, 2024-2035 ($ Million)
25. Asia-Pacific Prediabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)
26. Asia-Pacific Prediabetes Market Research And Analysis By Route Of Administration, 2024-2035 ($ Million)
27. Asia-Pacific Prediabetes Market Research And Analysis By Age Group, 2024-2035 ($ Million)
28. Rest Of The World Prediabetes Market Research And Analysis By Region, 2024-2035 ($ Million)
29. Rest Of The World Prediabetes Market Research And Analysis By Drug Class, 2024-2035 ($ Million)
30. Rest Of The World Prediabetes Market Research And Analysis By Route Of Administration, 2024-2035 ($ Million)
31. Rest Of The World Prediabetes Market Research And Analysis By Age Group, 2024-2035 ($ Million)
1. Global Prediabetes Market Share By Drug Class, 2024 Vs 2035 (%)
2. Global Biguanide (Metformin) Prediabetes Market Share By Region, 2024 Vs 2035 (%)
3. Global Thiazolidinediones (TZDs) Prediabetes Market Share By Region, 2024 Vs 2035 (%)
4. Global Glucagon-Like Peptide-1 Agonists (GLP-1) Prediabetes Market Share By Region, 2024 Vs 2035 (%)
5. Global SGLT2 Inhibitors Prediabetes Market Share By Region, 2024 Vs 2035 (%)
6. Global DPP-4 Inhibitors Prediabetes Market Share By Region, 2024 Vs 2035 (%)
7. Global Other Drug Class Prediabetes Market Share By Region, 2024 Vs 2035 (%)
8. Global Prediabetes Market Share By Route Of Administration, 2024 Vs 2035 (%)
9. Global Oral Prediabetes Market Share By Region, 2024 Vs 2035 (%)
10. Global Injectable Prediabetes Market Share By Region, 2024 Vs 2035 (%)
11. Global Prediabetes Market Share By Age Group, 2024 Vs 2035 (%)
12. Global Prediabetes Children Market Share By Region, 2024 Vs 2035 (%)
13. Global Prediabetes Adult Market Share By Region, 2024 Vs 2035 (%)
14. Global Prediabetes Elderly Market Share By Region, 2024 Vs 2035 (%)
15. US Prediabetes Market Size, 2024-2035 ($ Million)
16. Canada Prediabetes Market Size, 2024-2035 ($ Million)
17. UK Prediabetes Market Size, 2024-2035 ($ Million)
18. France Prediabetes Market Size, 2024-2035 ($ Million)
19. Germany Prediabetes Market Size, 2024-2035 ($ Million)
20. Italy Prediabetes Market Size, 2024-2035 ($ Million)
21. Spain Prediabetes Market Size, 2024-2035 ($ Million)
22. Russia Prediabetes Market Size, 2024-2035 ($ Million)
23. Rest Of Europe Prediabetes Market Size, 2024-2035 ($ Million)
24. India Prediabetes Market Size, 2024-2035 ($ Million)
25. China Prediabetes Market Size, 2024-2035 ($ Million)
26. Japan Prediabetes Market Size, 2024-2035 ($ Million)
27. South Korea Prediabetes Market Size, 2024-2035 ($ Million)
28. Australia And New Zealand Prediabetes Market Size, 2024-2035 ($ Million)
29. ASEAN Economies Prediabetes Market Size, 2024-2035 ($ Million)
30. Rest Of Asia-Pacific Prediabetes Market Size, 2024-2035 ($ Million)
31. Latin America Prediabetes Market Size, 2024-2035 ($ Million)
32. Middle East and Africa Prediabetes Market Size, 2024-2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Prediabetes market in 2024 is estimated to be around $0.35 billion.
North America holds the largest share in the Prediabetes market.
Leading players in the Prediabetes market include Abbott Laboratories, AstraZeneca, Eli Lilly and Co., Medtronic MiniMed, Inc., Nordisk A/S, among others., among others.
Prediabetes market is expected to grow at a CAGR of 11.3% from 2025 to 2035.
Increasing prevalence of obesity, sedentary lifestyles, and growing awareness about early diabetes management are driving the Prediabetes Market growth.
